Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniela Toneatto

Showing results (1-10 of 50) with videos related to

Pageof 5
Sort By:
Expert Review of Vaccines|April 5, 2017
Emerging experience with meningococcal serogroup B protein vaccinesDaniela Toneatto, Mariagrazia Pizza, Vega Masignani, et al.
Human Vaccines & Immunotherapeutics|June 28, 2019
Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adultsFederico Martinón-Torres, Terry Nolan, Daniela Toneatto, et al.
Clinical and Vaccine Immunology : CVI|December 24, 2010
Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolatesAlan Kimura, Daniela Toneatto, Annett Kleinschmidt, et al.
Msphere|November 17, 2021
Immunogenicity and Safety of Investigational MenABCWY Vaccine and of 4CMenB and MenACWY Vaccines Administered Concomitantly or Alone: a Phase 2 Randomized Study of Adolescents and Young AdultsJiří Beran, Daniel Dražan, Igwebuike Enweonye, et al.
Drugs|December 17, 2013
A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development programMiguel O'Ryan, Jeffrey Stoddard, Daniela Toneatto, et al.
Expert Review of Vaccines|February 24, 2015
Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigenKate L Seib, Maria Scarselli, Maurizio Comanducci, et al.
Therapeutic Advances in Vaccines|January 2, 2015
Prevention of rare diseases: how revolutionary techniques can help vulnerable individuals-the example of serogroup B meningococcal infectionE David McIntosh, Victor Carey, Daniela Toneatto, et al.
Human Vaccines|September 10, 2011
The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humansDaniela Toneatto, Shevqet Ismaili, Ellen Ypma, et al.
Vaccine|July 5, 2015
Meningococcal serogroup B vaccine (4CMenB): Booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old childrenTimo Vesikari, Roman Prymula, Elizabeth Merrall, et al.
Human Vaccines & Immunotherapeutics|November 27, 2014
A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I)Roman Prymula, Susanna Esposito, Gian Vincenzo Zuccotti, et al.
Pageof 5

Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
Expert Review of Vaccines|April 5, 2017
Emerging experience with meningococcal serogroup B protein vaccinesDaniela Toneatto, Mariagrazia Pizza, Vega Masignani, et al.
Human Vaccines & Immunotherapeutics|June 28, 2019
Persistence of the immune response after 4CMenB vaccination, and the response to an additional booster dose in infants, children, adolescents, and young adultsFederico Martinón-Torres, Terry Nolan, Daniela Toneatto, et al.
Clinical and Vaccine Immunology : CVI|December 24, 2010
Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolatesAlan Kimura, Daniela Toneatto, Annett Kleinschmidt, et al.
Msphere|November 17, 2021
Immunogenicity and Safety of Investigational MenABCWY Vaccine and of 4CMenB and MenACWY Vaccines Administered Concomitantly or Alone: a Phase 2 Randomized Study of Adolescents and Young AdultsJiří Beran, Daniel Dražan, Igwebuike Enweonye, et al.
Drugs|December 17, 2013
A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development programMiguel O'Ryan, Jeffrey Stoddard, Daniela Toneatto, et al.
Expert Review of Vaccines|February 24, 2015
Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigenKate L Seib, Maria Scarselli, Maurizio Comanducci, et al.
Therapeutic Advances in Vaccines|January 2, 2015
Prevention of rare diseases: how revolutionary techniques can help vulnerable individuals-the example of serogroup B meningococcal infectionE David McIntosh, Victor Carey, Daniela Toneatto, et al.
Human Vaccines|September 10, 2011
The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humansDaniela Toneatto, Shevqet Ismaili, Ellen Ypma, et al.
Vaccine|July 5, 2015
Meningococcal serogroup B vaccine (4CMenB): Booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old childrenTimo Vesikari, Roman Prymula, Elizabeth Merrall, et al.
Human Vaccines & Immunotherapeutics|November 27, 2014
A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I)Roman Prymula, Susanna Esposito, Gian Vincenzo Zuccotti, et al.
Pageof 5